Piroxicam

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Piroxicam

Examples of brand names: Felden [DE]

ATC code: M01AC01

Main use (for orientation): Pain; inflammation

Documented research summary

CBD + piroxicam did not consistently enhance CBD cytotoxicity in canine bladder tumour cells. Individual dose comparisons were significant, but an overall/IC50 effect was not established. No statement of human safety.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0331

Type of result: Preclinical, predominantly null finding

Observation: No consistent enhancement/IC50 effect with CBD; individual concentration comparisons differed.

Mechanism: Preclinical enhancement analysis of cell viability.

Study type: Canine urothelial carcinoma cell lines AXA/Orig/SH

Context studied: Piroxicam 20 µM, CBD 0.03–300 µM, 24 h, low serum concentration.

Clinical interpretation: Clinical significance undetermined

Limitations and uncertainties: No Chou–Talalay combination index for piroxicam because there was no suitable dose–response curve. No clinical pharmacokinetic or safety extrapolation.

Original sources for this finding: Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells. [BMED34352013]

References and access status

[C_LABEL_D0169] PIROXICAM (PIROXICAM) CAPSULE [BRYANT RANCH PREPACK]

Original source / bibliographic reference

Authors: BRYANT RANCH PREPACK

Year: 2026

Source type: US Structured Product Label

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED34352013] Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells.

Original source / bibliographic reference

Authors: Inkol JM, Hocker SE, Mutsaers AJ.

Year: 2021

Source type: Publication; title and abstract reviewed

DOI: 10.1371/journal.pone.0255591

PMID: 34352013

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility